2013
DOI: 10.1002/dvdy.24031
|View full text |Cite
|
Sign up to set email alerts
|

A new look at cytoskeletal NOS‐1 and β‐dystroglycan changes in developing muscle and brain in control and mdx dystrophic mice

Abstract: Background: Loss of dystrophin profoundly affects muscle function and cognition. Changes in the dystrophin-glycoprotein complex (DGC) including disruption of nitric oxide synthase (NOS-1) may result from loss of dystrophin or secondarily after muscle damage. Disruptions in NOS-1 and beta-dystroglycan (bDG) were examined in developing diaphragm, quadriceps, and two brain regions between control and mdx mice at embryonic day E18 and postnatal days P1, P10, and P28. Age-dependent differential muscle loading allow… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
11
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 14 publications
(14 citation statements)
references
References 94 publications
(123 reference statements)
3
11
0
Order By: Relevance
“…Concomitantly, combined therapy showed more marked effects on the levels of b‐DG, leading to almost normal levels of this protein in the DIA in comparison to DFZ alone. b‐DG, which is reduced in the dystrophic fibres, is a main component of the dystrophin‐protein complex that links the cytoskeleton to the extracellular matrix, protects muscle fibres from mechanical stress and confers sarcolemmal reliance during contraction . Therefore, it is possible to suggest that the combined therapy improved sarcolemma stability by significantly increasing the levels of b‐DG, in agreement to other reports .…”
Section: Discussionsupporting
confidence: 89%
See 1 more Smart Citation
“…Concomitantly, combined therapy showed more marked effects on the levels of b‐DG, leading to almost normal levels of this protein in the DIA in comparison to DFZ alone. b‐DG, which is reduced in the dystrophic fibres, is a main component of the dystrophin‐protein complex that links the cytoskeleton to the extracellular matrix, protects muscle fibres from mechanical stress and confers sarcolemmal reliance during contraction . Therefore, it is possible to suggest that the combined therapy improved sarcolemma stability by significantly increasing the levels of b‐DG, in agreement to other reports .…”
Section: Discussionsupporting
confidence: 89%
“…b-DG, which is reduced in the dystrophic fibres, is a main component of the dystrophin-protein complex that links the cytoskeleton to the extracellular matrix, protects muscle fibres from mechanical stress 18,19 and confers sarcolemmal reliance during contraction. 20 Therefore, it is possible to suggest that the combined therapy improved sarcolemma stability by significantly increasing the levels of b-DG, in agreement to other reports. 21,22 The increase in b-DG observed here may be related to the actions of both therapies (primarily the combined) in decreasing the levels of MMP-9 because DFZ and DOX have anti-MMP-9 activity 4,23 and b-DG is a substrate of MMP-9.…”
Section: Myoprotective Effectssupporting
confidence: 89%
“…Dystrophin is important in maintaining fiber membrane integrity . It is reported to have additional function as a “molecular clock,” because it decreases in muscle with increasing age .…”
Section: Discussionmentioning
confidence: 99%
“…During this process and the accompanying growth, skeletal muscle fibers increase significantly in breadth (the mean diameter of hind limb muscle fibers increases fivefold) and even more in length (the average muscle fiber length for an adult is 20-30 mm, which is 1,000-fold longer than a mononucleated cell) (44). DG and the DGC are critical during this dynamic phase of sarcolemmal expansion (45)(46)(47). Contraction-induced injury before the onset of necrosis has been investigated in muscles of mouse pups deficient for both dystrophin and utrophin (48).…”
Section: Discussionmentioning
confidence: 99%